Haleon PLC Sponsored ADR (HLN) - What Are Investment Firms Thinking About This Stock?

Haleon logo with Consumer Staples background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give Haleon a “Moderate Buy” consensus: Of 10 analysts, two rate it Buy, two Strong Buy, five Hold and one Sell; the average 12-month price target is $4.90.
  • HLN opened at $9.21, within its 52-week range of $8.38 to $11.28. The company’s market capitalization is about $40.54 billion.
  • Several institutional investors increased their positions, including Arrowstreet Capital and Goldman Sachs; institutional investors and hedge funds own 6.67% of Haleon’s stock.
  • MarketBeat previews the top five stocks to own by December 1st.

Haleon PLC Sponsored ADR (NYSE:HLN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation, two have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $4.90.

A number of research analysts have commented on the company. Morgan Stanley reiterated an "overweight" rating on shares of Haleon in a research report on Thursday, August 6th. Wall Street Zen lowered Haleon from a "buy" rating to a "hold" rating in a research note on Saturday, October 3rd. Berenberg Bank reiterated a "buy" rating on shares of Haleon in a report on Wednesday, August 5th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Haleon in a research note on Friday, September 25th. Finally, Zacks Research cut shares of Haleon from a "hold" rating to a "strong sell" rating in a research report on Thursday, October 22nd.

Read Our Latest Report on HLN

Haleon Stock Performance

HLN stock opened at $9.21 on Tuesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.69 and a quick ratio of 0.52. The company has a 50 day moving average price of $9.33 and a 200 day moving average price of $9.71. Haleon has a fifty-two week low of $8.38 and a fifty-two week high of $11.28. The stock has a market capitalization of $40.54 billion, a PE ratio of 23.60, a price-to-earnings-growth ratio of 2.13 and a beta of 0.15.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Mondrian Investment Partners LTD bought a new stake in shares of Haleon in the 3rd quarter valued at about $158,737,000. Arrowstreet Capital Limited Partnership lifted its stake in Haleon by 82.8% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 14,674,518 shares of the company's stock valued at $146,892,000 after purchasing an additional 6,647,329 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Haleon by 75.5% during the third quarter. Goldman Sachs Group Inc. now owns 9,467,279 shares of the company's stock worth $85,206,000 after purchasing an additional 4,072,837 shares during the period. Principal Financial Group Inc. grew its holdings in Haleon by 27,393.7% during the first quarter. Principal Financial Group Inc. now owns 2,803,530 shares of the company's stock worth $28,063,000 after purchasing an additional 2,793,333 shares during the period. Finally, Bank of America Corp DE grew its holdings in Haleon by 17.0% during the first quarter. Bank of America Corp DE now owns 10,934,228 shares of the company's stock worth $109,452,000 after purchasing an additional 1,586,230 shares during the period. Institutional investors and hedge funds own 6.67% of the company's stock.

About Haleon

(Get Free Report)

Haleon plc is a global consumer healthcare company that develops and sells nonprescription health products. Its portfolio spans oral health, pain relief, vitamins and supplements, respiratory health, digestive health, and therapeutic skin care. Its brands include Sensodyne, parodontax and Polident in oral care; Advil, Panadol and Voltaren for pain relief; and Centrum, Emergen-C and Theraflu in supplements and respiratory care. Haleon sells its products in markets around the world. Haleon became an independent public company in 2022 after separating from GSK.

Further Reading

Analyst Recommendations for Haleon (NYSE:HLN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Haleon Right Now?

Before you consider Haleon, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.

While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines